Survival and psychomotor development with early betaine treatment in patients with severe methylenetetrahydrofolate reductase deficiency

JAMA Neurology

Volumn 71, Issue 2, 2014, Pages 188-194

  Diekman, Eugene F ^a   De Koning, Tom J ^b   Verhoeven Duif, Nanda M ^a   Rovers, Maroeska M ^c,d   Van Hasselt, Peter M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETAINE;

ARTICLE; DISEASE SEVERITY; DRUG EFFECT; EARLY INTERVENTION; ENZYME DEFICIENCY; HUMAN; METHYLENETETRAHYDROFOLATE REDUCTASE DEFICIENCY; MORTALITY; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT; SURVIVAL RATE; SYSTEMATIC REVIEW; THERAPY DELAY; TREATMENT OUTCOME;

ADOLESCENT; BETAINE; CHILD; CHILD, PRESCHOOL; FEMALE; HOMOCYSTINURIA; HUMANS; INFANT; INFANT, NEWBORN; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MUSCLE SPASTICITY; PSYCHOMOTOR DISORDERS; PSYCHOTIC DISORDERS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893826296     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.4915     Document Type: Article

References (25)

1. Lewis SJ, Ebrahim S, Davey Smith G. Meta-analysis of MTHFR 677C->T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005;331(7524):1053.
2. Prasad AN, Rupar CA, Prasad C. Methylenetetrahydrofolate reductase (MTHFR) deficiency and infantile epilepsy. Brain Dev. 2011;33(9):758-769.
3. Fattal-Valevski A, Bassan H, Korman SH, Lerman-Sagie T, Gutman A, Harel S. Methylenetetrahydrofolate reductase deficiency: importance of early diagnosis. J Child Neurol. 2000;15(8):539-543.
4. Forges T, Chery C, Audonnet S, Feillet F, Gueant J-L. Life-threatening methylenetetrahydrofolate reductase (MTHFR) deficiency with extremely early onset: characterization of two novel mutations in compound heterozygous patients. Mol Genet Metab. 2010;100(2):143-148.
5. Al Tawari AA, Ramadan DG, Neubauer D, Heberle LC, Al Awadi F. An early onset form of methylenetetrahydrofolate reductase deficiency: a report of a family from Kuwait. Brain Dev. 2002;24(5):304-309.
6. Schiff M, Benoist J-F, Tilea B, Royer N, Giraudier S, Ogier de Baulny H. Isolated remethylation disorders: do our treatments benefit patients [published correction appears in J Inherit Metab Dis. 2011;34(6);1229]?
7. J Inherit Metab Dis. 2011;34(1):137-145.
8. Strauss KA, Morton DH, Puffenberger EG, et al. Prevention of brain disease from severe 5, 10-methylenetetrahydrofolate reductase deficiency. Mol Genet Metab. 2007;91(2):165-175.
9. Brandt N, Christensen E, Skovby F, Djernes B. Treatment of methylene-tetrahydrofolate reductase from the neonatal period. Paper presented at: 24th Annual Symposium of the Society for the Study of Inborn Errors of Metabolism; 1986; Amersfoort, the Netherlands.
10. Wendel U, Bremer HJ. Betaine in the treatment of homocystinuria due to 5, 10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr. 1984;142(2):147-150.
11. Holme E, Kjellman B, Ronge E. Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency. Arch Dis Child. 1989;64(7):1061-1064.
12. Schwahn BC, Laryea MD, Chen Z, et al. Betaine rescue of an animal model with methylenetetrahydrofolate reductase deficiency. Biochem J. 2004;382(pt 3):831-840.
13. Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med. 2001;134(4):330-334.
14. Ucar SK, Koroglu OA, Berk O, et al. Titration of betaine therapy to optimize therapy in an infant with 5, 10-methylenetetrahydrofolate reductase deficiency. Eur J Pediatr. 2010;169(2):241-243.
15. Abeling NG, van Gennip AH, Blom H, et al. Rapid diagnosis and methionine administration: basis for a favourable outcome in a patient with methylene tetrahydrofolate reductase deficiency. J Inherit Metab Dis. 1999;22(3):240-242.
16. Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S. Determining optimal therapy: randomized trials in individual patients. N Engl J Med. 1986;314(14):889-892.
17. Refsum H, Grindflek AW, Ueland PM, et al. Screening for serum total homocysteine in newborn children. Clin Chem. 2004;50(10):1769-1784.
18. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam. 1968;65(4):281-393.
19. Haworth JC, Dilling LA, Surtees RA, et al. Symptomatic and asymptomatic methylenetetrahydrofolate reductase deficiency in two adult brothers. Am J Med Genet. 1993;45(5):572-576.
20. Bishop L, Kanoff R, Charnas L, Krenzel C, Berry SA, Schimmenti LA. Severe methylenetetrahydrofolate reductase (MTHFR) deficiency: a case report of nonclassical homocystinuria. J Child Neurol. 2008;23(7):823-828.
21. Ronge E, Kjellman B. Long term treatment with betaine in methylenetetrahydrofolate reductase deficiency. Arch Dis Child. 1996;74(3):239-241.
22. Urreizti R, Moya-García AA, Pino-Ángeles A, et al. Molecular characterization of five patients with homocystinuria due to severe methylenetetrahydrofolate reductase deficiency. Clin Genet. 2010;78(5):441-448.
23. Tonetti C, Amiel J, Munnich A, Zittoun J. Impact of new mutations in the methylenetetrahydrofolate reductase gene assessed on biochemical phenotypes: a familial study. J Inherit Metab Dis. 2001;24(8):833-842.
24. Tallur KK, Johnson DA, Kirk JM, Sandercock P A G, Minns RA. Folate-induced reversal of leukoencephalopathy and intellectual decline in methylene-tetrahydrofolate reductase deficiency: variable response in siblings. Dev Med Child Neurol. 2005;47(1):53-56.
25. Al-Essa MA, Al Amir A, Rashed M, et al. Clinical, fluorine-18 labeled 2-fluoro-2-deoxyglucose positron emission tomography of the brain, MR spectroscopy, and therapeutic attempts in methylenetetrahydrofolate reductase deficiency. Brain Dev. 1999;21(5):345-349.